Abstract
To The Editor: The strategy of suppressing ventricular ectopy by pharmaceutical means in the peri-infarct period has been fraught with disappointment and has tinted our view of the approach, as can be seen in the accompanying editorial by Patton.1 The Cardiac Arrhythmia Suppression Trial showed that premature ventricular beat suppression did not prevent sudden cardiac death, but rather increased the risk secondary to the proarrhythmic effects of the antiarrhythmic drugs used.2 Several other trials have reaffirmed these results. In the European Myocardial …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
